Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
UBS
US Department of Justice
Deloitte
Healthtrust
Cantor Fitzgerald

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,163,684

« Back to Dashboard

Which drugs does patent 7,163,684 protect, and when does it expire?

Patent 7,163,684 protects FORTEO and is included in one NDA.

This patent has sixty-five patent family members in thirty-four countries.

Summary for Patent: 7,163,684
Title:Method of increasing bone toughness and stiffness and reducing fractures
Abstract:The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracture, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.
Inventor(s): Gaich; Gregory A. (Indianapolis, IN), Dere; Willard H. (Westlake Village Ventura, CA), Hock; Janet M. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:11/098,894
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,163,684
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,163,684
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,163,684

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED ➤ Sign Up
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE ➤ Sign Up
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No ➤ Sign Up ➤ Sign Up FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Argus Health
Queensland Health
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.